Davita Inc (DVA) Shares Bought by OppenheimerFunds Inc.
OppenheimerFunds Inc. boosted its stake in Davita Inc (NYSE:DVA) by 4.8% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 4,263,038 shares of the company’s stock after acquiring an additional 196,721 shares during the quarter. OppenheimerFunds Inc. owned 2.57% of Davita worth $305,361,000 as of its most recent filing with the SEC.
Other institutional investors also recently added to or reduced their stakes in the company. Cornerstone Wealth Management LLC acquired a new stake in Davita during the second quarter worth approximately $409,000. Janney Montgomery Scott LLC lifted its position in Davita by 4.5% during the second quarter. Janney Montgomery Scott LLC now owns 19,009 shares of the company’s stock worth $1,320,000 after acquiring an additional 811 shares during the last quarter. Raymond James Financial Services Advisors Inc. raised its position in shares of Davita by 21.4% in the second quarter. Raymond James Financial Services Advisors Inc. now owns 30,087 shares of the company’s stock valued at $2,089,000 after buying an additional 5,307 shares in the last quarter. TD Asset Management Inc. raised its position in shares of Davita by 16.8% in the second quarter. TD Asset Management Inc. now owns 130,924 shares of the company’s stock valued at $9,091,000 after buying an additional 18,838 shares in the last quarter. Finally, Sumitomo Mitsui Trust Holdings Inc. raised its position in shares of Davita by 4.5% in the second quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 477,191 shares of the company’s stock valued at $33,136,000 after buying an additional 20,561 shares in the last quarter. 85.76% of the stock is currently owned by hedge funds and other institutional investors.
A number of equities research analysts have recently weighed in on DVA shares. Zacks Investment Research downgraded shares of Davita from a “hold” rating to a “sell” rating in a research report on Tuesday, November 13th. ValuEngine downgraded shares of Davita from a “buy” rating to a “hold” rating in a research report on Wednesday, October 17th. UBS Group started coverage on shares of Davita in a research report on Thursday, November 15th. They issued a “sell” rating and a $64.00 price target for the company. TheStreet downgraded shares of Davita from a “b-” rating to a “c+” rating in a research report on Thursday, November 8th. Finally, JPMorgan Chase & Co. upgraded shares of Davita from an “underweight” rating to a “neutral” rating in a research report on Thursday, September 13th. Two investment analysts have rated the stock with a sell rating, six have assigned a hold rating and four have assigned a buy rating to the company. The company has a consensus rating of “Hold” and an average price target of $80.16.
Davita (NYSE:DVA) last released its quarterly earnings results on Wednesday, November 7th. The company reported $0.56 earnings per share for the quarter, missing analysts’ consensus estimates of $0.89 by ($0.33). The business had revenue of $2.85 billion during the quarter, compared to analyst estimates of $2.93 billion. Davita had a net margin of 5.39% and a return on equity of 13.87%. The firm’s quarterly revenue was up 3.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.81 earnings per share. On average, sell-side analysts anticipate that Davita Inc will post 3.56 earnings per share for the current year.
ILLEGAL ACTIVITY NOTICE: “Davita Inc (DVA) Shares Bought by OppenheimerFunds Inc.” was first posted by Watch List News and is owned by of Watch List News. If you are reading this piece of content on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://www.watchlistnews.com/davita-inc-dva-shares-bought-by-oppenheimerfunds-inc/2662452.html.
Davita Company Profile
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
Read More: What is a Reverse Stock Split?
Receive News & Ratings for Davita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Davita and related companies with MarketBeat.com's FREE daily email newsletter.